$AMBS : LymPro Alzheimer's Disease Diagnostic Blood Test

Current Status: LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer’s disease diagnosis. LymPro is ready to move into a Phase 2 validation study for CLIA certification that will be done by Memory Dx.

LymPro was designed with the purpose of diagnosing Alzheimer’s in its mild to moderate stage, a population of patients currently being tested in numerous clinical studies with amyloid-beta targeting strategies. LymPro works by identifying immune-based biomarkers in the blood of Alzheimer’s patients, diagnosing Alzheimer’s and allowing physicians to definitively differentiate Alzheimer’s disease from other forms of dementia. This patient-specific identification has the potential to become an invaluable tool for Alzheimer’s disease clinical trials, where there has been a well-documented history of patient recruitment errors related to inaccurate diagnosis of Alzheimer’s.   Amarantus licensed the LymPro Alzheimer's Disease Diagnostic Blood Test from Memory Dx, LLC in December 2012.

http://www.amarantus.com/diagnostic-developme...blood-test